Abstract
Recent data suggest that many tumors, such as malignant gliomas, have disrupted pRB function, either because of RB-1 gene mutations or as a result of mutations affecting upstream regulators of pRB such as cyclin D1 or p16/INK4a/MTS1 (ref. 1–5). Tumor suppression by pRB has been linked to its ability to repress E2F-responsive promoters such as the E2F-1 promoter6,7. Thus, a prediction, which has not yet been demonstrated experimentally in vivo, is that E2F-responsive promoters should be more active in tumor cells relative to normal cells because of an excess of “free” E2F and loss of pRB/E2F represser complexes. We demonstrate that adenoviral vectors that contain transgenes driven by the E2F-1 promoter can mediate tumor-selective gene expression in vivo, allowing for eradication of established gliomas with significantly less normal tissue toxicity than seen with standard adenoviral vectors. Our data indicate that de-repression of the E2F-1 promoter occurs in cancer cells in vivo, a finding that can be exploited to design viral vectors that mediate tumor-selective gene expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell 81, 323–330 (1995).
He, J. et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54, 5804–5807 (1994).
Ueki, K. et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56, 150–153 (1996).
Jen, J. et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353–6358 (1994).
Schmidt, E.E., Ichimura, K., Reifenberger, G. & Collins, V.P. CDKN2/p16/MTSI/ gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54, 6321–6324 (1994).
Adams, P.D. & Kaelin, W.G. Transcriptional control by E2F. Semin. Cancer Biol. 6, 99–108 (1995).
Sellers, W.R., Neuman, E. & Kaelin, W.G. The retinoblastoma protein contains a potent transrepression domain which induces a cell-cycle block when bound to DNA. Proc. Natl. Acad. Sci. USA 92, 11544–11548 (1995).
Tevosian, S.G., Paulson, K.E., Branson, R. & Yee, A.S. Expression of the E2F-1/DP-1 transcription factor in murine development. Cell Growth Differ. 7, 43–52 (1996).
Kaelin, W.G. et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70, 351–364 (1992).
Neuman, E., Flemington, E.K., Sellers, W.R. & Kaelin, W.G. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 14, 6607–6615 (1994).
Johnson, D.G., Kiyoshi, O. & Nevins, J.R. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8, 1514–1525 (1994).
Hsiao, K.-M., McMahon, S.L. & Farnham, P. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev. 8, 1526–1537 (1994).
Johnson, D.G. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene 11, 1685–1692 (1995).
McGrory, W.J., Bautista, D.S. & Graham, F.L. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163, 614–617 (1988).
Ghosh-Choudhury, G., Haj-Ahmad, Y., Brinkley, P., Rudy, J. & Graham, F.L. Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 50, 161–171 (1986).
Culver, K.W. et al. In vivo gene transfer with retroviral-vector producer cells for treatment of experimental brain tumors. Science 256, 1550–1552 (1992).
Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. & Oldfield, E.H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 3475–3485 (1993).
Fine, H.A. Prospects for gene therapy as an innovative approach to malignant gliomas. Perspect. Neural. Surg. 5, 115–127 (1994).
Manome, Y. et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside In vitro and in vivo. Nature Med. 2, 567–573 (1996).
Goodman, J. et al. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir; pathologic, radiographic, and molecular studies. Hum. Gene Ther. 7, 1241–50 (1996).
Fults, D., Brockmeyer, D., Tullous, M.W., Pedone, C.A. & Cawthone, R.M. p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res. 52, 674–679 (1992).
Dong, Y. et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum. Gene Ther. 7, 713–720 (1996).
Graham, F.L., Smiley, J., Russel, W.C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59–72 (1977).
Kobayashi, N., Allen, N., Clendenon, N.R. & Ko, L.-W. An improved rat brain-tumor model. J. Neurosurg. 53, 808–815 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Parr, M., Manome, Y., Tanaka, T. et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3, 1145–1149 (1997). https://doi.org/10.1038/nm1097-1145
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm1097-1145
This article is cited by
-
Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing
Molecular Therapy (2010)
-
Transgene expression of α tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity
Cancer Gene Therapy (2009)
-
NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors
Cancer Gene Therapy (2009)
-
The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR
Cancer Gene Therapy (2007)